文献速递心力衰竭与心肌病心律失常

射血分数降低与保留的心力衰竭患者房颤消融的系统综述与荟萃分析

Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
PubMed 文献 · JAMA Cardiol · 2024-01-01

该系统综述与荟萃分析纳入12项随机临床试验共2465例心衰合并房颤患者,比较导管消融与常规心率或节律控制。

要点

  • 导管消融可降低HFrEF合并房颤患者心衰事件风险,但HFpEF患者未见获益。
  • HFrEF患者导管消融与心血管死亡风险降低相关,HFpEF患者未发现差异。
  • 全因死亡风险在HFrEF与HFpEF两组间无显著交互差异。

核心结论

  • 导管消融与HFrEF患者心衰事件风险降低相关,但在HFpEF患者中获益有限或无效。

研究设计与样本

  • 系统检索MEDLINE、Embase和Cochrane Central从建库至2023年9月的文献,纳入平行组随机临床试验,最终纳入12项RCT和4项亚研究,共2465例参与者(平均年龄65.3岁,女性658例占26.7%),其中HFrEF 1552例,HFpEF 913例。

主要发现

  • 全因死亡风险在HFrEF(RR 0.63;95%CI 0.47-0.86)与HFpEF(RR 0.95;95%CI 0.39-2.30)组间无差异,交互作用P=0.39。

关键数值与推荐

  • 主要结局为心衰事件,定义为心衰住院、临床显著心衰恶化或非计划就诊加强治疗。
  • 纳入标准为心衰、NYHA功能分级II级或以上、有阵发性或持续性房颤病史的患者。

临床怎么用

  • 对于HFrEF合并房颤患者,导管消融可作为降低心衰事件和心血管死亡风险的策略。
  • 对于HFpEF合并房颤患者,导管消融的获益尚不明确,需个体化决策并等待正在进行的试验结果。

局限性

  • HFpEF亚组样本量较小,事件数有限,结果可能不够精确。
  • 正在进行的试验可能进一步阐明导管消融在HFpEF中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Catheter ablation is associated with reduced heart failure (HF) hospitalization and death in select patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF). However, the benefit in patients with HF with preserved ejection fraction (HFpEF) is uncertain. OBJECTIVE: To investigate whether catheter ablation for AF is associated with reduced HF-related outcomes according to HF phenotype. DATA SOURCE: A systematic search of MEDLINE, Embase, and Cochrane Central was conducted among studies published from inception to September 2023. STUDY SELECTION: Parallel-group randomized clinical trials (RCTs) comparing catheter ablation with conventional rate or rhythm control therapies in patients with HF, New York Heart Association functional class II or greater, and a history of paroxysmal or persistent AF were included. Pairs of independent reviewers screened 7531 titles and abstracts, of which 12 RCTs and 4 substudies met selection criteria. DATA EXTRACTION AND SYNTHESIS: Data were abstracted in duplicate according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Pooled effect estimates were calculated using random-effects Mantel-Haenszel models. Interaction P values were used to test for subgroup differences. MAIN OUTCOMES AND MEASURES: The primary outcome was HF events, defined as HF hospitalization, clinically significant worsening of HF, or unscheduled visits to a clinician for treatment intensification. Secondary outcomes included cardiovascular and all-cause mortality. RESULTS: A total of 12 RCTs with 2465 participants (mean [SD] age, 65.3 [9.7] years; 658 females [26.7%]) were included; there were 1552 participants with HFrEF and 913 participants with HFpEF. Compared with conventional rate or rhythm control, catheter ablation was associated with reduced risk of HF events in HFrEF (risk ratio [RR], 0.59; 95% CI, 0.48-0.72), while there was no benefit in patients with HFpEF (RR, 0.93; 95% CI, 0.65-1.32) (P for interaction = .03). Catheter ablation was associated with reduced risk of cardiovascular death compared with conventional therapies in HFrEF (RR, 0.49; 95% CI, 0.34-0.70) but a differential association was not detected in HFpEF (RR, 0.91; 95% CI, 0.46-1.79) (P for interaction = .12). Similarly, no difference in the association of catheter ablation with all-cause mortality was found between HFrEF (RR vs conventional therapies, 0.63; 95% CI, 0.47-0.86) and HFpEF (RR vs conventional therapies, 0.95; 95% CI, 0.39-2.30) groups (P for interaction = .39). CONCLUSIONS AND RELEVANCE: This study found that catheter ablation for AF was associated with reduced risk of HF events in patients with HFrEF but had limited or no benefit in HFpEF. Results from ongoing trials may further elucidate the role of catheter ablation for AF in HFpEF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Oraii, McIntyre, Parkash, et al. Atrial Fibrillation Ablation in Heart Failure With Reduced vs Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2024. PMID: 38656292. doi:10.1001/jamacardio.2024.0675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。